[{"orgOrder":0,"company":"Tokyo Women's Medical University","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Desflurane","moa":"Potassium channel subfamily K member 3 | Potassium channel subfamily K member 10 | GABA-A receptor; anion channel | Potassium channel subfamily K member 2 | Potassium channel subfamily K member 9 | Potassium channel subfamily K member 18 | Glycine receptor (alpha-1\/beta)","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Tokyo Women's Medical University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tokyo Women's Medical University \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Tokyo Women's Medical University \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Juntendo University","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Desflurane","moa":"Potassium channel subfamily K member 3 | Potassium channel subfamily K member 10 | GABA-A receptor; anion channel | Potassium channel subfamily K member 2 | Potassium channel subfamily K member 9 | Potassium channel subfamily K member 18 | Glycine receptor (alpha-1\/beta)","graph1":"Oncology","graph2":"Undisclosed","graph3":"Juntendo University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juntendo University \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Juntendo University \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Ohio State University","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Desflurane","moa":"Potassium channel subfamily K member 3 | Potassium channel subfamily K member 10 | GABA-A receptor; anion channel | Potassium channel subfamily K member 2 | Potassium channel subfamily K member 9 | Potassium channel subfamily K member 18 | Glycine receptor (alpha-1\/beta)","graph1":"Undisclosed","graph2":"Phase III","graph3":"Ohio State University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ohio State University \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Ohio State University \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Hahnemann University Hospital","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Desflurane","moa":"Potassium channel subfamily K member 3 | Potassium channel subfamily K member 10 | GABA-A receptor; anion channel | Potassium channel subfamily K member 2 | Potassium channel subfamily K member 9 | Potassium channel subfamily K member 18 | Glycine receptor (alpha-1\/beta)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Hahnemann University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Hahnemann University Hospital \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Hahnemann University Hospital \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Nobuyuki Katori","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Desflurane","moa":"Potassium channel subfamily K member 3 | Potassium channel subfamily K member 10 | GABA-A receptor; anion channel | Potassium channel subfamily K member 2 | Potassium channel subfamily K member 9 | Potassium channel subfamily K member 18 | Glycine receptor (alpha-1\/beta)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Nobuyuki Katori","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nobuyuki Katori \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Nobuyuki Katori \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Bego\u00f1a Quintana Villamandos","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Desflurane","moa":"Potassium channel subfamily K member 3 | Potassium channel subfamily K member 10 | GABA-A receptor; anion channel | Potassium channel subfamily K member 2 | Potassium channel subfamily K member 9 | Potassium channel subfamily K member 18 | Glycine receptor (alpha-1\/beta)","graph1":"Nephrology","graph2":"Phase IV","graph3":"Bego\u00f1a Quintana Villamandos","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bego\u00f1a Quintana Villamandos \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Bego\u00f1a Quintana Villamandos \/ Baxter Healthcare Corporation"}]

Find Clinical Drug Pipeline Developments & Deals for Desflurane

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Begoña Quintana Villamandos

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Begoña Quintana Villamandos

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Desflurane is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Renal Insufficiency.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 16, 2019

                          Lead Product(s) : Desflurane

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase IV

                          Sponsor : Baxter Healthcare Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Juntendo University

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Juntendo University

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Desflurane is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Lung Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 24, 2014

                          Lead Product(s) : Desflurane

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Baxter Healthcare Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Nobuyuki Katori

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Nobuyuki Katori

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Desflurane is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Aortic Valve Stenosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 24, 2013

                          Lead Product(s) : Desflurane

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Baxter Healthcare Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Tokyo Women's Medical University

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Tokyo Women's Medical University

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Desflurane is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 15, 2013

                          Lead Product(s) : Desflurane

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Baxter Healthcare Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Hahnemann University Hospital

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Hahnemann University Hospital

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Desflurane is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Vaginal Diseases.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 08, 2011

                          Lead Product(s) : Desflurane

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase IV

                          Sponsor : Baxter Healthcare Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Ohio State University

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Ohio State University

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Desflurane is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 13, 2010

                          Lead Product(s) : Desflurane

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase III

                          Sponsor : Baxter Healthcare Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank